New combo therapy could boost fluid removal in heart failure

NCT ID NCT07372040

Recruiting now Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three different drugs—empagliflozin, acetazolamide, and metolazone—added to standard water pills (loop diuretics) in 66 adults hospitalized for acute decompensated heart failure. The goal is to see which drug works best at increasing urine output over three days. Researchers will also measure changes in heart stress markers. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin, acetazolamide, and metolazone
What this could lead to: If successful, this could identify a better add-on therapy to help heart failure patients get rid of excess fluid more effectively during hospitalization.
What could go wrong: This is a small, early-phase trial with only 66 participants, so results may not apply to all patients. The drugs also carry risks like electrolyte imbalances or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE DECOMPENSATED HEART FAILURE

Contacts and locations

Locations

Tanta university
RECRUITING

Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.